Abstract Growing evidence supports the important role of the tumor microenvironment (TME) in cancer biology. A defining aspect of the glioma TME is the unique composition and structure of its extracellular matrix (ECM), which enables tumor cells to overcome the inhibitory barriers of the adult central nervous system (CNS). In this way, the TME plays a role in glioma invasion and the cellular heterogeneity that distinguishes these tumors. Brain Enriched Hyaluronan Binding (BEHAB)/brevican (B/b), is a CNS-specific ECM constituent and is upregulated in the glioma TME. Previous studies have shown B/b exerts a pro-invasive function, suggesting it may represent a target to reduce glioma pathogenesis. Herein, we also provide evidence that B/b expression is enriched in the glioma initiating cell (GIC) niche. We demonstrate that B/b plays roles in the pathological progression, aggressiveness, and lethality of tumors derived from human GICs and traditional glioma cell lines. Interestingly, we found that B/b is not required to maintain the defining phenotypic properties of GICs and thereby acts primarily in late stages of glioma progression. This study suggests that the increased expression of B/b in the TME is a valuable therapeutic target for glioma.
Introduction
The tumor microenvironment (TME) plays an important role in cancer biology by facilitating interactions between tumor cells and their surrounding environment [1] . As in other cancers, the TME is important in the pathogenesis of glioma. High-grade gliomas (HGGs) are the most common and fatal form of primary intracranial tumors. Despite significant progress in developing more effective adjuvant therapies for these tumors, patient mortality remains high [2] . Several aspects of glioma pathophysiology enable tumor cells to evade therapeutic treatments [3] , including their ability to invade the normal surrounding brain tissue and their highly heterogeneous cellular composition.
The ability of glioma tumor cells to invade the normally inhibitory barriers of the CNS is unique, as even the most invasive peripheral tumors rarely invade the surrounding neural tissue [4] . This portends a unique interaction between glioma cells, the TME and the normal brain environment that facilitates glioma invasion. The TME also provides a niche for establishing and maintaining the heterogeneity of cellular subpopulations within glioma tumors, including the treatment-resistant glioma initiating cell (GIC) population [5] [6] [7] . The broad functionality of the glioma TME in mediating aspects of glioma progression makes it an attractive therapeutic target [8] .
The neural extracellular matrix (ECM) protein, brain enriched hyaluronan binding (BEHAB)/brevican (B/b), is a major constituent of the glioma TME. B/b is a CNS-specific member of the lectican family of chondroitin sulfate proteoglycans [9] [10] [11] . B/b expression is significantly increased in gliomas relative to normal brain [12] . B/b has been correlated with gliomas exhibiting proneural-like phenotypes [13] [14] [15] , however B/b is overexpressed in the vast majority of HGGs and likely contributes to the progression of all molecular subtypes [12] .
Several isoforms of B/b are increased in human HGGs compared to normal brain tissue, including glycosylated isoforms that are unique to gliomas [12, [16] [17] [18] [19] [20] [21] [22] . Differentiated glioma cell lines implanted intracranially recapitulate the endogenous expression of B/b in clinical gliomas [12] . However, these cells lose B/b expression when implanted subcutaneously or grown in vitro [12] , making it difficult to study the molecular mechanisms of the native protein and the role of B/b in a physiologically relevant environment. Forced overexpression of B/b through transfection and subsequent cleavage of the full-length protein to release bioactive fragments increases brain tumor aggressiveness in rodent models by enhancing tumor cell invasion [18, 20, 22, 23] . A recent study demonstrated that knockdown of transfected B/b reduces the growth of subcutaneously implanted gliomas [24] . However, the effect of suppressing endogenous levels of B/b, which is naturally upregulated in gliomas, has not been previously investigated. Moreover, the effects of suppressing B/b in the critical GIC population still remain unknown.
The purpose of this study was to investigate the effects of B/b knockdown in intracranial invasive glioma and its potential impact in the GIC population to reduce tumor formation and prolong survival. Our results suggest that B/b may be a passenger gene during initial stages of tumor formation but may have significant impact in the late, more invasive stages of glioma progression as GICs become differentiated in the tumor parenchyma.
Materials and methods

Cell culture
CNS-1 cells were cultured as previously described [19] . GIC lines 0627 and 0913 were previously described [25] . GICs were cultured in a modified Sato's Medium [26] supplemented with 10 ng/mL EGF and bFGF.
shRNA-mediated knockdown of B/b siRNAs were transformed into shRNAs and cloned into the pRNAT-U6.1/Hygro vector (GenScript, Piscataway, NJ) for rodent models and the lentiviral delivery vector pLentiLox3.7 (pLL3.7) [27] (Addgene, Cambridge, MA, USA) for human GICs. Lentiviral production was performed as previously described [28] . To verify B/b knockdown, sample preparation and Western blotting was carried out as specified previously [21, 29] . Isotopic in situ hybridization of B/b mRNA was performed as previously described [9] , in all cases no signal was observed from sense probes.
Cell viability assays
For CNS1 cells, the CellTiter 96 Ò AQ ueous One Solution Cell Proliferation Assay kit was used (Promega, Madison, WI). For GICs, a standard MTT assay was conducted on cells growing as non-adherent spheres. Absorbance levels were normalized to wells containing only media. Statistical comparisons were performed by two-way ANOVA.
Differentiation assay
GICs were seeded on coverslips pre-coated with 5 lg/mL laminin (Millipore). Media was changed to Sato's Medium Base without EGF and bFGF that was supplemented with 10 % FBS and cells were collected at 12 days in vitro (DIV). Non-differentiated cells were plated on laminincoated coverslips and collected at 3 DIV.
Human tumors
Paraffin-embedded human brain tumors classified as glioblastoma (GBMs) were fixed in 4 % formalin and prepared at 5 lM sections. Sections were rehydrated and heatmediated antigen retrieval was completed with sodium citrate buffer.
Stereotaxic tumor implantation
For in vivo studies using CNS-1 cells or GICs, adult female Lewis rats or nude CD-1 mice were used, respectively (Charles River Laboratory, New Brunswick, NJ). Protocols were approved by Yale University and State University of New York Upstate Medical School animal care committees.
For intracranial CNS-1 cell grafts, 1.5 9 10 5 cells in 1.5 lL was injected into the right thalamus of rats at 3.2 mm posterior and 2.3 mm to the right of Bregma at a depth of 5.5 mm. Survival was plotted according to the method of Kaplan and Meier and statistical significance was determined using the Log-Rank (Mantel-Cox) test.
For intracranial GIC grafts, 1.1 9 10 6 cells in 1.5 lL was injected into the right striatum of CD-1 nude mice at 0.5 mm anterior and 2.0 mm to the right of Bregma at a depth of 3.5 mm. Pairs of control and shB/b animals were established at the time of tumor implantation. Both animals in the pair were sacrificed when one was showing signs of neurological deterioration. To control for differences in survival times, analyses were carried out between animal pairs. Statistical analysis for survival was carried by LogRank (Mantel-Cox) test.
Tumor analysis
Free-floating 40 lM coronal sections were collected and every sixth (CNS-1) or eighth (GICs) sections were analyzed for tumor volume reconstruction. GFP expression by implanted tumor cells was used to define tumor boundaries for histological analysis. Tumor volume was reconstructed based on the method of Cavalieri [30] , using the formula V = (0. 24) [ P 1 n (y)]-(0.04)y max . Anteroposterior spread (A/P spread) was determined by calculating the distance spanning sections with sparse tumor cells at the most rostral and caudal limits and was used as a measure of tumor cell dispersion. For CNS-1 tumors, statistical significance was determined by a standard two-tailed, equal variance t test. Due to the paired nature of studies done with GICs, statistical significance was determined with the Wilcoxon matched-pairs signed rank test. The experimenter was blinded to the identity of all animals.
The numbers of animals used for in vivo studies are specified in the text as (n = numerical value). In all studies, statistical significance was determined by a p value that was less than 0.05. See also Supplemental Methods. A list of shRNA and primer sequences and antibodies used in this study is detailed in Supplemental Tables 1 and 2 .
Results
B/b knockdown in an invasive rodent model decreases tumor size and prolongs survival
The CNS-1 cell line is a reliable rodent model of invasive glioma, as the invasive characteristics and syngeneic nature of intracranial grafts created with this cell line are similar to human gliomas [17, 18, 31] . A fundamental question remains as to whether reducing B/b expression, which is naturally upregulated in glioma, could reduce the progression of these tumors. Therefore, we evaluated the effects of reducing B/b expression through shRNA-mediated knockdown on the pathophysiology of tumors created using the wildtype CNS-1 rodent model of invasive glioma.
To overcome the absence of endogenous B/b expression in CNS-1 cells in vitro, control and shRNA constructs designed against B/b (designated shB/b) were co-transfected with cDNA encoding rat full-length B/b. Western blot analysis confirmed the ability of shB/b constructs to reduce the expression of rat B/b in CNS-1 cells (Fig. 1a) . Stable transfection with these constructs showed no effect on cell proliferation in vitro by MTT assays (data not shown).
To analyze the functional consequences of reduced B/b we turned to an in vivo intracranial graft model, in which both the induction and importance of B/b has been previously detailed [12, 18] . Wildtype CNS-1 cells were engineered to stably express either control or shB/b and were injected to the thalamus of adult rats to establish intracranial grafts. At 12 days post implantation (DPI) the brains of these animals were collected for histological examination (Figs. 1b, c). Manual tumor volume reconstruction was derived using the Cavalieri estimate. Control tumors (n = 11) had a mean total tumor volume of 71.44 ± 9.595 mm 3 while tumors expressing shB/b (n = 11) experienced a 34 % reduction in mean volume, at 47.36 ± 2.130 mm 3 (p = 0.024) (Fig. 1d) . Control tumors had a mean anteroposterior spread (A/P spread) of 5.415 ± 0.283 mm while tumors expressing shB/b experienced a 27 % reduction in A/P spread, at 3.990 ± 0.075 mm (p = \ 0.001) (Fig. 1e) .
To confirm that the reduction in tumor growth was due to reduced B/b expression, we performed in situ hybridization and verified that shB/b effectively reduced endogenous B/b expression in CNS-1 derived tumors (Fig. 2a) . We next evaluated animal survival. Rats with control gliomas (n = 9) reached their survival endpoint within 16.56 ± 2.79 DPI on average. Rats harboring gliomas with either of the two independent shB/b constructs (n = 10) survived 22 % longer, with mean overall-survival of 20.6 ± 2.3 and 19.8 ± 0.87 DPI (p \ 0.01) (Fig. 2b) .
B/b expression is enriched in the glioma initiating cell niche and expressed by GICs in vitro
We next evaluated the distribution of B/b protein in human HGGs. Interestingly, B/b was non-homogeneously distributed throughout the tumor core of human GBM tumors, wherein distinct sub-regions stained more intensely for B/b than others. We determined that sub-regions highly reactive for B/b preferentially surrounded cells that expressed Olig2 and CD133, markers of highly tumorigenic cell populations including the GIC subclass (Figs. 3a-c) .
To examine the role of B/b in the GIC population, we utilized two GIC cell lines 0627 and 0913 [25] . Although cultures of GICs have been documented to endogenously express the B/b gene (BCAN) in vitro [13] , its expression has not been studied in detail. We first evaluated the expression of BCAN by RT-PCR. As expected RT-PCR yielded no band in U373MG cells, while 0627 and 0913 GICs yielded an intensely reactive band for the BCAN gene (Fig. 3d) . Western blot analysis showed that both 0627 and 0913 cell lysates expressed full-length B/b protein, which resolved at *150 kD for both cell lines. In conditioned media samples, full-length B/b and the *80-90 kD C-terminal proteolytic cleavage fragment were primarily detected in 0627 and not 0913 GICs (Fig. 3e) .
B/b knockdown has no obvious effects on GIC phenotype in vitro
We next investigated the function of B/b in GICs. We hypothesized that while the function of B/b in traditional serum cultured glioma cell lines is primarily associated with tumor cell invasion, B/b may have additional functions to support the defining characteristics of GICs. Stable 0627 GICs expressing either the control plasmid or shRNA against human B/b (shB/b) were created. Western blot analysis confirmed that GICs expressing either independent shB/b construct significantly reduced all endogenous B/b protein isoforms (Fig. 4a) . Endogenous expression of B/b by GICs enabled us to investigate its physiological function using shRNA-mediated knockdown in vitro. We found that B/b knockdown had no effect on the growth potential of GICs in vitro (p = 0.6770) (Fig. 4b) . Likewise, the ability of GIC clones to form spheres between passages was not affected (Fig. 4c) . We further investigated the self-renewal capacity of GICs by analyzing the ability of single clones to form spheres and found no significant difference in the percentage of spheres formed (p = 0.4182) or their circumference (p = 0.1864) (Supplemental Fig. 1 ). We found no differences in the expression of cell-fate markers in undifferentiated conditions or in the ability of GICs to differentiate in response to serum after B/b knockdown (Figs. 4d, e) . We performed Transwell-migration assays using GICs and found no consistent differences in the migration or invasion of control and shB/b shRNA expressing cells in these assays (data not shown).
Genes encoding transcription factors oligodendrocyte lineage transcription factor 2 (OLIG2), delta-like 3 (DLL3), and achaete-scute complex homolog 1 (ASCL1) are highly expressed with BCAN in the pro-neural molecular subtype [13, 14] . Importantly, these genes play a significant role in maintaining the self-renewal and tumorigenic qualities of GICs [32, 33] . Therefore our findings suggested B/b is not an extracellular regulator of pro-neural gene expression. We confirmed the enriched expression of pro-neural genes OLIG2, ASCL1 and DLL3 in 0627 GICs relative to the traditional human cell line, U373MG (data not shown). We determined that a reduction in B/b expression could also be detected at the transcript level (p \ 0.01) and the expression of pro-neural transcription factors were not altered as a result of reduced B/b expression (Supplemental Fig. 2) .
B/b knockdown reduces aggressiveness in late stages of GIC-derived tumor pathogenesis
We reasoned that the function of B/b as a secreted protein may be best observed in the in vivo environment. Therefore, shRNA-expressing GICs were injected into the striatum of nude mice. Mice were evaluated until signs of neurological deterioration were detected. All animal pairs (n = 6) were sacrificed as a result of neurological deterioration that was observed in the control animal, but not in animals harboring shB/b-expressing tumors, with a median survival time of 62 DPI (p = 0.009). shB/b GIC-derived tumors had a 20 % reduction in mean tumor volume relative to controls. The decrease encroached on statistical significance by two-tailed Wilcoxon matched-pairs signed rank test (p = 0.0625) and was statistically significant by a one-tailed test (p = 0.008) (Fig. 5a ). The A/P spread of shB/b tumors relative to controls was significantly decreased, as determined by one-tailed Wilcoxon matchedpairs signed rank test (Fig. 5b, p = 0.011) . However, both control GICs and those expressing shB/b formed large intracranial masses. While the tumor burden was reduced, the morphology of individual cells at the rostral and medial/lateral tumor/stromal boundaries were similar in both control and shB/b GIC-derived tumors (Figs. 5c-f) .
To determine whether a reduction in tumor size in vivo was due to alterations in the ability of GICs to form intracranial grafts, we examined the histology of earlyengrafted GICs. Control (n = 4) or shB/b (n = 4) GICs were injected into the striatum of nude mice and harvested at 19 or 20 DPI prior to formation of large neoplasms. We found that both control and B/b shRNA expressing tumors engrafted similarly (Supplemental Fig. 3 ). Samples were either treated with a control buffer (-) or chondroitinase (chABC) to remove CS-GAG chains (?). Full-length B/b protein was detected around 150kD in both lysate and conditioned media samples (CM), while C-terminal proteolytic cleavage fragments resolved at *80 kD and were found primarily in conditioned media samples. The absence of an apparent molecular weight shift following chABC treatment (?) suggests B/b expressed by GICs is not extensively modified with CS-GAGs. a-tubulin was used as a loading control for lysate samples
Discussion
The CNS-specific expression of B/b [9, 10] , its significant upregulation and processing in gliomas and GICs suggest that B/b may uniquely contribute to the pathogenesis of these tumors. While overexpression of B/b has an evident enhancing effect on tumor growth and invasion [18, 20, 22, 23] , results from loss-of-function experiments have not conclusively demonstrated the impact of B/b suppression in a clinically-relevant setting [24] . Therefore, we conducted shRNA-mediated knockdown studies in intracranial models of invasive glioma, including GICderived models. Our results indicate a significant reduction in the volume of intracranial tumors and reduced A/P Our results showing B/b is enriched in the GIC niche and in cultured GICs led us to hypothesize that B/b may be required for the defining characteristics of this unique cellular subclass-including the ability to self-renew, differentiate, and generate tumors [25, 34, 35] . However, our results suggest that while B/b is highly expressed by GICs, it does not critically contribute to their maintenance or defining properties in vitro. Similarly, B/b knockdown did not affect the expression of other pro-neural genes (OLIG2, ASCL1 and DLL3). Since GICs harboring B/b shRNA were capable of forming intracranial grafts and giving rise to tumors, B/b appears as a passenger gene in vitro and during initial stages of tumor formation, but contributes to the end-stage progression of gliomas.
A potential 'late' gain-of-function of B/b in gliomas raises interesting questions about the progression of molecular mechanisms in the TME and remodeling of the ECM during tumor progression. Our previous work has shown B/b acts in gliomas to enhance tumor cell invasion only after cleavage of the full-length protein [20, 23] and subsequent release of a bioactive N-terminal fragment that activates EGFR signaling and increases cell association with a fibronectin-rich matrix [23] . Interestingly, the GICs used in this study express very low levels of fibronectin compared to differentiated glioma cell lines and did not bind to fibronectin (data not shown), potentially explaining the lack of effect following B/b knockdown in GICs in vitro. Since fibronectin is a pro-invasive and proangiogenic molecule secreted by glioma cells as the tumor progresses, we suggest that the effect we have seen following B/b knockdown in vivo could be explained by a decreased ability of tumor cells to interact with their own fibronectin-rich matrix, resulting in slowed tumor progression. Together, our work and previous findings suggest that the pro-invasive function of B/b may coincide with ECM remodeling that likely manifest following phenotypic changes of GICs during tumor progression. Future work focused on the relationship between B/b and fibronectin coexpression during tumor progression will likely reveal particular modes of B/b-mediated invasion that are context specific and shed light on its role in the pathogenesis of glioma.
In sum, our study suggests that B/b knockdown decreases the pathological progression of glioma and the expression of the B/b gene, BCAN, represents a potentially valuable therapeutic target. The extracellular and CNSspecific nature of B/b expression, the glioma-specific expression of unique isoforms, its upregulation in the vast majority of gliomas, and its abundance in the GIC niche support its promise as a target for the directed delivery of therapeutic agents. Additionally, the correlation between the B/b gene, BCAN, and other tumorigenic pro-neural genes suggests that common upstream mechanisms may regulate their expressions at the level of gene transcription. Identifying these regulatory mechanisms could provide the initial steps to developing novel glioma therapies.
